New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts
Research output: Contribution to journal › Journal article › Research › peer-review
The proposition of uPAR as a potential target in cancer therapy is advanced by its predominant expression at the invasive front of colorectal cancer (CRC) and its value as prognostic biomarker for poor survival in this disease. In this study, we provide the first in vivo proof-of-concept for a theranostic approach as treatment modality in a human xenograft colorectal cancer model.
| Original language | English |
|---|---|
| Journal | Nuclear Medicine and Biology |
| Volume | 39 |
| Issue number | 7 |
| Pages (from-to) | 962-9 |
| Number of pages | 8 |
| ISSN | 0969-8051 |
| DOIs | |
| Publication status | Published - Oct 2012 |
- Animals, Beta Particles, Cell Transformation, Neoplastic, Colorectal Neoplasms, Dideoxynucleosides, Female, HT29 Cells, Heterocyclic Compounds, 1-Ring, Humans, Lutetium, Mice, Molecular Targeted Therapy, Neoplasm Invasiveness, Oligopeptides, Positron-Emission Tomography, Radioisotopes, Receptors, Urokinase Plasminogen Activator, Substrate Specificity
Research areas
ID: 45945376